English

Denali Therapeutics Inc.

EDGAR

DNLI Quarterly report (10-Q) · filed 2026-08-06

Annual consolidated revenue for 2025: about USD 0, using the latest reported figures. The previous period, 2024, was about USD 0.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

3.6 million USD

2026 Q2 · USD

Exact inputs and evidence

Revenue: 3604000 USD Source

Operating margin

-3,622.11%

2026 Q2 · %

Exact inputs and evidence

Operating Income: -130541000 USD Source
Revenue: 3604000 USD Source

Operating cash flow

-97 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -228206000 USD Source
Operating Cash Flow: -131204000 USD Source

Free cash flow

-97.8 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -228206000 USD Source
Operating Cash Flow: -131204000 USD Source
Capital Expenditure: 3271000 USD Source
Capital Expenditure: 2466000 USD Source

Cash and cash equivalents: 202 million USD 2026-06-30 Source
Exact value

201530000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 160 million shares 2026-06-30 Source
Exact value

159755526 shares

Reported share-count change

9.66% · 14.1 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

145685442 shares · 2025-06-30· Source
159755526 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Net income

-511 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: -126902000 USD · 2025-07-01 – 2025-09-30 Source
Net income: -512540000 USD · 2025-01-01 – 2025-12-31 Source
Net income: -383991000 USD · 2025-01-01 – 2025-09-30 Source
Net income: -128447000 USD · 2026-01-01 – 2026-03-31 Source
Net income: -127553000 USD · 2026-04-01 – 2026-06-30 Source

Operating cash flow

-434 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -314062000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -206766000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -412600000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -314062000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -131204000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -228206000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -131204000 USD · 2026-01-01 – 2026-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-08-06.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 10 of 11 periods available· newest 2025-12-31
Operating income: 10 of 11 periods available· newest 2025-12-31
Net income: 10 of 11 periods available· newest 2025-12-31
Operating cash flow: 10 of 11 periods available· newest 2025-12-31
Capital expenditure: 10 of 11 periods available· newest 2025-12-31
Total assets: 9 of 11 periods available· newest 2025-12-31
Total liabilities: 9 of 11 periods available· newest 2025-12-31
Current assets: 9 of 11 periods available· newest 2025-12-31
Current liabilities: 9 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 10 of 11 periods available· newest 2025-12-31
long term debt: No compatible figures in this window
Shares outstanding: 9 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
USD 0

Prior period

USD 0

2024-01-01 – 2024-12-31
Current period

USD 0

2025-01-01 – 2025-12-31

Exact inputs and evidence

0 − 0 = 0 USD

0 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
0 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Denali Therapeutics Inc. · 2025-12-31 Denali Therapeutics Inc. (edgar:1714899) Year-over-year change in Revenue: 0 USD Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T23:15:23Z Snapshot: 913cbd83cd218e4e8bd06d80b237750247ba0058df259456e43d2aa2b5f864f5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1714899?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 0 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1714899/000171489926000021/dnli-20251231.htm#1729201 Filing: 000171489926000021 Input fundies:Revenue: 0 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1714899/000171489926000021/dnli-20251231.htm#1730116 Filing: 000171489926000021
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 89.77 million

Prior period

−USD 422.77 million

2024-01-01 – 2024-12-31
Current period

−USD 512.54 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-512540000 − -422773000 = -89767000 USD

-422773000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-512540000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Denali Therapeutics Inc. · 2025-12-31 Denali Therapeutics Inc. (edgar:1714899) Year-over-year change in Net income: -89767000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T23:15:23Z Snapshot: 913cbd83cd218e4e8bd06d80b237750247ba0058df259456e43d2aa2b5f864f5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1714899?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -512540000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1714899/000171489926000021/dnli-20251231.htm#2088438 Filing: 000171489926000021 Input fundies:NetIncome: -422773000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1714899/000171489926000021/dnli-20251231.htm#2089201 Filing: 000171489926000021
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 64.91 million

Prior period

−USD 347.69 million

2024-01-01 – 2024-12-31
Current period

−USD 412.6 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-412600000 − -347694000 = -64906000 USD

-347694000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-412600000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Denali Therapeutics Inc. · 2025-12-31 Denali Therapeutics Inc. (edgar:1714899) Year-over-year change in Operating cash flow: -64906000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T23:15:23Z Snapshot: 913cbd83cd218e4e8bd06d80b237750247ba0058df259456e43d2aa2b5f864f5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1714899?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -412600000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1714899/000171489926000021/dnli-20251231.htm#1440594 Filing: 000171489926000021 Input fundies:OperatingCashFlow: -347694000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1714899/000171489926000021/dnli-20251231.htm#1441244 Filing: 000171489926000021
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-40.3%

Prior period

USD 15.91 million

2024-01-01 – 2024-12-31
Current period

USD 9.5 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

9502000 − 15912000 = -6410000 USD

15912000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
9502000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Denali Therapeutics Inc. · 2025-12-31 Denali Therapeutics Inc. (edgar:1714899) Year-over-year change in Capital expenditure: -6410000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T23:15:23Z Snapshot: 913cbd83cd218e4e8bd06d80b237750247ba0058df259456e43d2aa2b5f864f5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1714899?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 9502000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1714899/000171489926000021/dnli-20251231.htm#1447362 Filing: 000171489926000021 Input fundies:CapitalExpenditure: 15912000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1714899/000171489926000021/dnli-20251231.htm#1447946 Filing: 000171489926000021
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue USD 0
Operating costs Derived USD 555.34 million
Operating income −USD 555.34 million
Tax, interest and other Derived −USD 42.8 million
Net income −USD 512.54 million

Cash

Operating cash flow −USD 412.6 million
Capital expenditure USD 9.5 million
Free cash flow Derived −USD 422.1 million

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2016 Not shown: operating income or net income is not reported.
2017 Not shown: operating income or net income is not reported.
2018 Operating loss: operating costs were 136% of revenue.
2019 Operating loss: operating costs were 899% of revenue.
2020 Net income was higher than operating income, so the split is not drawn.
2021 Operating loss: operating costs were 708% of revenue.
2022 Operating loss: operating costs were 414% of revenue.
2023 Operating loss: operating costs were 160% of revenue.
2024 Not shown: operating income or net income is not reported.
2025 Not shown: operating income or net income is not reported.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2016 2016-01-01 – 2016-12-31	0	87433000 Derived	-87433000	-781000 Derived	-86652000	-78042000 Derived	Source 2016-01-01 – 2016-12-31: 0 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: -87433000 USD Inspect Operating Income Open source 2016-01-01 – 2016-12-31: -86652000 USD Inspect Net Income Open source 2016-01-01 – 2016-12-31: -71908000 USD Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 6134000 USD Inspect Capital Expenditure Open source
2017 2017-01-01 – 2017-12-31	0	90140000 Derived	-90140000	-1955000 Derived	-88185000	-79510000 Derived	Source 2017-01-01 – 2017-12-31: 0 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: -90140000 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -88185000 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: -76635000 USD Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 2875000 USD Inspect Capital Expenditure Open source
2018 2018-01-01 – 2018-12-31	129160000	175532000 Derived	-46372000	-10132000 Derived	-36240000	46723000 Derived	Source 2018-01-01 – 2018-12-31: 129160000 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: -46372000 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: -36240000 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: 50116000 USD Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 3393000 USD Inspect Capital Expenditure Open source
2019 2019-01-01 – 2019-12-31	26678000	239862000 Derived	-213184000	-15570000 Derived	-197614000	-169495000 Derived	Source 2019-01-01 – 2019-12-31: 26678000 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -213184000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -197614000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -151576000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 17919000 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	335659000	272941000 Derived	62718000	-8418000 Derived	71136000	413057000 Derived	Source 2020-01-01 – 2020-12-31: 335659000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: 62718000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: 71136000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: 416152000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 3095000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	48661000	344412000 Derived	-295751000	-5170000 Derived	-290581000	-219889000 Derived	Source 2021-01-01 – 2021-12-31: 48661000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -295751000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -290581000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -211389000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 8500000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	108463000	449207000 Derived	-340744000	-14753000 Derived	-325991000	-262549000 Derived	Source 2022-01-01 – 2022-12-31: 108463000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -340744000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -325991000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -244716000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 17833000 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	330531000	527230000 Derived	-196699000	-51475000 Derived	-145224000	-370930000 Derived	Source 2023-01-01 – 2023-12-31: 330531000 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -196699000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -145224000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -357991000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 12939000 USD Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	0	487341000 Derived	-487341000	-64568000 Derived	-422773000	-363606000 Derived	Source 2024-01-01 – 2024-12-31: 0 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -487341000 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -422773000 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: -347694000 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 15912000 USD Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	0	555342000 Derived	-555342000	-42802000 Derived	-512540000	-422102000 Derived	Source 2025-01-01 – 2025-12-31: 0 USD Inspect Revenue Open source 2025-01-01 – 2025-12-31: -555342000 USD Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -512540000 USD Inspect Net Income Open source 2025-01-01 – 2025-12-31: -412600000 USD Inspect Operating Cash Flow Open source 2025-01-01 – 2025-12-31: 9502000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 0 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Revenue	0	Revenue: 0 Open source
20172017-12-31	Revenue	0	Revenue: 0 Open source
20182018-12-31	Revenue	129160000	Revenue: 129160000 Open source
20192019-12-31	Revenue	26678000	Revenue: 26678000 Open source
20202020-12-31	Revenue	335659000	Revenue: 335659000 Open source
20212021-12-31	Revenue	48661000	Revenue: 48661000 Open source
20222022-12-31	Revenue	108463000	Revenue: 108463000 Open source
20232023-12-31	Revenue	330531000	Revenue: 330531000 Open source
20242024-12-31	Revenue	0	Revenue: 0 Open source
20252025-12-31	Revenue	0	Revenue: 0 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-100% 2024

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Year over year	No prior comparable period	Revenue: 0 Open source
20172017-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source
20182018-12-31	Year over year	No prior comparable period	Revenue: 129160000 Open source Revenue: 0 Open source
20192019-12-31	Year over year	-79.3%	Revenue: 26678000 Open source Revenue: 129160000 Open source
20202020-12-31	Year over year	1,158.2%	Revenue: 335659000 Open source Revenue: 26678000 Open source
20212021-12-31	Year over year	-85.5%	Revenue: 48661000 Open source Revenue: 335659000 Open source
20222022-12-31	Year over year	122.9%	Revenue: 108463000 Open source Revenue: 48661000 Open source
20232023-12-31	Year over year	204.7%	Revenue: 330531000 Open source Revenue: 108463000 Open source
20242024-12-31	Year over year	-100%	Revenue: 0 Open source Revenue: 330531000 Open source
20252025-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -59.5% 2023

Net margin -43.9% 2023

Free cash flow margin -112.2% 2023

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Operating margin	Not reported	Operating Income: -87433000 Open source Revenue: 0 Open source
20172017-12-31	Operating margin	Not reported	Operating Income: -90140000 Open source Revenue: 0 Open source
20182018-12-31	Operating margin	-35.9%	Operating Income: -46372000 Open source Revenue: 129160000 Open source
20192019-12-31	Operating margin	-799.1%	Operating Income: -213184000 Open source Revenue: 26678000 Open source
20202020-12-31	Operating margin	18.7%	Operating Income: 62718000 Open source Revenue: 335659000 Open source
20212021-12-31	Operating margin	-607.8%	Operating Income: -295751000 Open source Revenue: 48661000 Open source
20222022-12-31	Operating margin	-314.2%	Operating Income: -340744000 Open source Revenue: 108463000 Open source
20232023-12-31	Operating margin	-59.5%	Operating Income: -196699000 Open source Revenue: 330531000 Open source
20242024-12-31	Operating margin	Not reported	Operating Income: -487341000 Open source Revenue: 0 Open source
20252025-12-31	Operating margin	Not reported	Operating Income: -555342000 Open source Revenue: 0 Open source
20162016-12-31	Net margin	Not reported	Net Income: -86652000 Open source Revenue: 0 Open source
20172017-12-31	Net margin	Not reported	Net Income: -88185000 Open source Revenue: 0 Open source
20182018-12-31	Net margin	-28.1%	Net Income: -36240000 Open source Revenue: 129160000 Open source
20192019-12-31	Net margin	-740.7%	Net Income: -197614000 Open source Revenue: 26678000 Open source
20202020-12-31	Net margin	21.2%	Net Income: 71136000 Open source Revenue: 335659000 Open source
20212021-12-31	Net margin	-597.2%	Net Income: -290581000 Open source Revenue: 48661000 Open source
20222022-12-31	Net margin	-300.6%	Net Income: -325991000 Open source Revenue: 108463000 Open source
20232023-12-31	Net margin	-43.9%	Net Income: -145224000 Open source Revenue: 330531000 Open source
20242024-12-31	Net margin	Not reported	Net Income: -422773000 Open source Revenue: 0 Open source
20252025-12-31	Net margin	Not reported	Net Income: -512540000 Open source Revenue: 0 Open source
20162016-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -71908000 Open source Capital Expenditure: 6134000 Open source
20172017-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -76635000 Open source Capital Expenditure: 2875000 Open source
20182018-12-31	Free cash flow margin	36.2%	Revenue: 129160000 Open source Operating Cash Flow: 50116000 Open source Capital Expenditure: 3393000 Open source
20192019-12-31	Free cash flow margin	-635.3%	Revenue: 26678000 Open source Operating Cash Flow: -151576000 Open source Capital Expenditure: 17919000 Open source
20202020-12-31	Free cash flow margin	123.1%	Revenue: 335659000 Open source Operating Cash Flow: 416152000 Open source Capital Expenditure: 3095000 Open source
20212021-12-31	Free cash flow margin	-451.9%	Revenue: 48661000 Open source Operating Cash Flow: -211389000 Open source Capital Expenditure: 8500000 Open source
20222022-12-31	Free cash flow margin	-242.1%	Revenue: 108463000 Open source Operating Cash Flow: -244716000 Open source Capital Expenditure: 17833000 Open source
20232023-12-31	Free cash flow margin	-112.2%	Revenue: 330531000 Open source Operating Cash Flow: -357991000 Open source Capital Expenditure: 12939000 Open source
20242024-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -347694000 Open source Capital Expenditure: 15912000 Open source
20252025-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -412600000 Open source Capital Expenditure: 9502000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -412.6M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Operating cash flow	-71908000	Operating Cash Flow: -71908000 Open source
20172017-12-31	Operating cash flow	-76635000	Operating Cash Flow: -76635000 Open source
20182018-12-31	Operating cash flow	50116000	Operating Cash Flow: 50116000 Open source
20192019-12-31	Operating cash flow	-151576000	Operating Cash Flow: -151576000 Open source
20202020-12-31	Operating cash flow	416152000	Operating Cash Flow: 416152000 Open source
20212021-12-31	Operating cash flow	-211389000	Operating Cash Flow: -211389000 Open source
20222022-12-31	Operating cash flow	-244716000	Operating Cash Flow: -244716000 Open source
20232023-12-31	Operating cash flow	-357991000	Operating Cash Flow: -357991000 Open source
20242024-12-31	Operating cash flow	-347694000	Operating Cash Flow: -347694000 Open source
20252025-12-31	Operating cash flow	-412600000	Operating Cash Flow: -412600000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -422.1M 2025

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Free cash flow	-78042000	Operating Cash Flow: -71908000 Open source Capital Expenditure: 6134000 Open source
20172017-12-31	Free cash flow	-79510000	Operating Cash Flow: -76635000 Open source Capital Expenditure: 2875000 Open source
20182018-12-31	Free cash flow	46723000	Operating Cash Flow: 50116000 Open source Capital Expenditure: 3393000 Open source
20192019-12-31	Free cash flow	-169495000	Operating Cash Flow: -151576000 Open source Capital Expenditure: 17919000 Open source
20202020-12-31	Free cash flow	413057000	Operating Cash Flow: 416152000 Open source Capital Expenditure: 3095000 Open source
20212021-12-31	Free cash flow	-219889000	Operating Cash Flow: -211389000 Open source Capital Expenditure: 8500000 Open source
20222022-12-31	Free cash flow	-262549000	Operating Cash Flow: -244716000 Open source Capital Expenditure: 17833000 Open source
20232023-12-31	Free cash flow	-370930000	Operating Cash Flow: -357991000 Open source Capital Expenditure: 12939000 Open source
20242024-12-31	Free cash flow	-363606000	Operating Cash Flow: -347694000 Open source Capital Expenditure: 15912000 Open source
20252025-12-31	Free cash flow	-422102000	Operating Cash Flow: -412600000 Open source Capital Expenditure: 9502000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

11.5% 2025

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2016-12-31	Liabilities / assets	Not reported	No source recorded
20172017-12-31	Liabilities / assets	4.3%	Total Liabilities: 20925000 Open source Total Assets: 486721000 Open source
20182018-12-31	Liabilities / assets	17.4%	Total Liabilities: 115139000 Open source Total Assets: 661984000 Open source
20192019-12-31	Liabilities / assets	28.6%	Total Liabilities: 158341000 Open source Total Assets: 553231000 Open source
20202020-12-31	Liabilities / assets	28.3%	Total Liabilities: 453749000 Open source Total Assets: 1604280000 Open source
20212021-12-31	Liabilities / assets	31.5%	Total Liabilities: 441871000 Open source Total Assets: 1404162000 Open source
20222022-12-31	Liabilities / assets	28.6%	Total Liabilities: 417812000 Open source Total Assets: 1460242000 Open source
20232023-12-31	Liabilities / assets	10.7%	Total Liabilities: 122963000 Open source Total Assets: 1153917000 Open source
20242024-12-31	Liabilities / assets	10.5%	Total Liabilities: 144496000 Open source Total Assets: 1374180000 Open source
20252025-12-31	Liabilities / assets	11.5%	Total Liabilities: 131093000 Open source Total Assets: 1144854000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

9.16× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
2016-12-31	Current assets / current liabilities	Not reported	No source recorded
20172017-12-31	Current assets / current liabilities	28.92×	Current Assets: 409607000 Open source Current Liabilities: 14164000 Open source
20182018-12-31	Current assets / current liabilities	14.67×	Current Assets: 480836000 Open source Current Liabilities: 32786000 Open source
20192019-12-31	Current assets / current liabilities	9.48×	Current Assets: 430031000 Open source Current Liabilities: 45344000 Open source
20202020-12-31	Current assets / current liabilities	20.86×	Current Assets: 1495655000 Open source Current Liabilities: 71699000 Open source
20212021-12-31	Current assets / current liabilities	2.37×	Current Assets: 897234000 Open source Current Liabilities: 378245000 Open source
20222022-12-31	Current assets / current liabilities	3.77×	Current Assets: 1372319000 Open source Current Liabilities: 363922000 Open source
20232023-12-31	Current assets / current liabilities	13.65×	Current Assets: 1064137000 Open source Current Liabilities: 77982000 Open source
20242024-12-31	Current assets / current liabilities	8.46×	Current Assets: 864436000 Open source Current Liabilities: 102208000 Open source
20252025-12-31	Current assets / current liabilities	9.16×	Current Assets: 900658000 Open source Current Liabilities: 98351000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2016 2016-01-01 – 2016-12-31	−USD 86.65 million Exact value Exact value: -86652000 USD 2016-01-01 – 2016-12-31: -86652000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Denali Therapeutics Inc. · 2016-12-31 Denali Therapeutics Inc. (edgar:1714899) Net Income: -86652000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T23:15:23Z Snapshot: 913cbd83cd218e4e8bd06d80b237750247ba0058df259456e43d2aa2b5f864f5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1714899/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -86652000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1714899/000171489919000015/dnli-20181231.htm#2757193 Filing: 000171489919000015 The citation records this snapshot. The page link may show a newer release later.	−USD 71.91 million Exact value Exact value: -71908000 USD 2016-01-01 – 2016-12-31: -71908000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Denali Therapeutics Inc. · 2016-12-31 Denali Therapeutics Inc. (edgar:1714899) Operating Cash Flow: -71908000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T23:15:23Z Snapshot: 913cbd83cd218e4e8bd06d80b237750247ba0058df259456e43d2aa2b5f864f5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1714899/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -71908000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1714899/000171489919000015/dnli-20181231.htm#1771159 Filing: 000171489919000015 The citation records this snapshot. The page link may show a newer release later.	USD 6.13 million Exact value Exact value: 6134000 USD 2016-01-01 – 2016-12-31: 6134000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Denali Therapeutics Inc. · 2016-12-31 Denali Therapeutics Inc. (edgar:1714899) Capital Expenditure: 6134000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T23:15:23Z Snapshot: 913cbd83cd218e4e8bd06d80b237750247ba0058df259456e43d2aa2b5f864f5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1714899/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 6134000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1714899/000171489919000015/dnli-20181231.htm#1778594 Filing: 000171489919000015 The citation records this snapshot. The page link may show a newer release later.	−USD 78.04 million Calculation and evidence -71908000 − 6134000 USD Exact free cash flow: -78042000 USD 2016-01-01 – 2016-12-31: -71908000 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 6134000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Denali Therapeutics Inc. · 2016-12-31 Denali Therapeutics Inc. (edgar:1714899) Free cash flow: -78042000 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T23:15:23Z Snapshot: 913cbd83cd218e4e8bd06d80b237750247ba0058df259456e43d2aa2b5f864f5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1714899?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -71908000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1714899/000171489919000015/dnli-20181231.htm#1771159 Filing: 000171489919000015 Input fundies:CapitalExpenditure: 6134000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1714899/000171489919000015/dnli-20181231.htm#1778594 Filing: 000171489919000015 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	−USD 88.19 million Exact value Exact value: -88185000 USD 2017-01-01 – 2017-12-31: -88185000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Denali Therapeutics Inc. · 2017-12-31 Denali Therapeutics Inc. (edgar:1714899) Net Income: -88185000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T23:15:23Z Snapshot: 913cbd83cd218e4e8bd06d80b237750247ba0058df259456e43d2aa2b5f864f5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1714899/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -88185000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1714899/000171489920000026/dnli-20191231.htm#1923972 Filing: 000171489920000026 The citation records this snapshot. The page link may show a newer release later.	−USD 76.64 million Exact value Exact value: -76635000 USD 2017-01-01 – 2017-12-31: -76635000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Denali Therapeutics Inc. · 2017-12-31 Denali Therapeutics Inc. (edgar:1714899) Operating Cash Flow: -76635000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T23:15:23Z Snapshot: 913cbd83cd218e4e8bd06d80b237750247ba0058df259456e43d2aa2b5f864f5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1714899/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -76635000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1714899/000171489920000026/dnli-20191231.htm#1978814 Filing: 000171489920000026 The citation records this snapshot. The page link may show a newer release later.	USD 2.88 million Exact value Exact value: 2875000 USD 2017-01-01 – 2017-12-31: 2875000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Denali Therapeutics Inc. · 2017-12-31 Denali Therapeutics Inc. (edgar:1714899) Capital Expenditure: 2875000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T23:15:23Z Snapshot: 913cbd83cd218e4e8bd06d80b237750247ba0058df259456e43d2aa2b5f864f5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1714899/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2875000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1714899/000171489920000026/dnli-20191231.htm#1987985 Filing: 000171489920000026 The citation records this snapshot. The page link may show a newer release later.	−USD 79.51 million Calculation and evidence -76635000 − 2875000 USD Exact free cash flow: -79510000 USD 2017-01-01 – 2017-12-31: -76635000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 2875000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Denali Therapeutics Inc. · 2017-12-31 Denali Therapeutics Inc. (edgar:1714899) Free cash flow: -79510000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T23:15:23Z Snapshot: 913cbd83cd218e4e8bd06d80b237750247ba0058df259456e43d2aa2b5f864f5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1714899?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -76635000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1714899/000171489920000026/dnli-20191231.htm#1978814 Filing: 000171489920000026 Input fundies:CapitalExpenditure: 2875000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1714899/000171489920000026/dnli-20191231.htm#1987985 Filing: 000171489920000026 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 36.24 million Exact value Exact value: -36240000 USD 2018-01-01 – 2018-12-31: -36240000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Denali Therapeutics Inc. · 2018-12-31 Denali Therapeutics Inc. (edgar:1714899) Net Income: -36240000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T23:15:23Z Snapshot: 913cbd83cd218e4e8bd06d80b237750247ba0058df259456e43d2aa2b5f864f5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1714899/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -36240000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1714899/000171489921000033/dnli-20201231.htm#2673012 Filing: 000171489921000033 The citation records this snapshot. The page link may show a newer release later.	USD 50.12 million Exact value Exact value: 50116000 USD 2018-01-01 – 2018-12-31: 50116000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Denali Therapeutics Inc. · 2018-12-31 Denali Therapeutics Inc. (edgar:1714899) Operating Cash Flow: 50116000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T23:15:23Z Snapshot: 913cbd83cd218e4e8bd06d80b237750247ba0058df259456e43d2aa2b5f864f5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1714899/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 50116000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1714899/000171489921000033/dnli-20201231.htm#1708563 Filing: 000171489921000033 The citation records this snapshot. The page link may show a newer release later.	USD 3.39 million Exact value Exact value: 3393000 USD 2018-01-01 – 2018-12-31: 3393000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Denali Therapeutics Inc. · 2018-12-31 Denali Therapeutics Inc. (edgar:1714899) Capital Expenditure: 3393000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T23:15:23Z Snapshot: 913cbd83cd218e4e8bd06d80b237750247ba0058df259456e43d2aa2b5f864f5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1714899/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3393000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1714899/000171489921000033/dnli-20201231.htm#1715503 Filing: 000171489921000033 The citation records this snapshot. The page link may show a newer release later.	USD 46.72 million Calculation and evidence 50116000 − 3393000 USD Exact free cash flow: 46723000 USD 2018-01-01 – 2018-12-31: 50116000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 3393000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Denali Therapeutics Inc. · 2018-12-31 Denali Therapeutics Inc. (edgar:1714899) Free cash flow: 46723000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T23:15:23Z Snapshot: 913cbd83cd218e4e8bd06d80b237750247ba0058df259456e43d2aa2b5f864f5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1714899?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 50116000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1714899/000171489921000033/dnli-20201231.htm#1708563 Filing: 000171489921000033 Input fundies:CapitalExpenditure: 3393000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1714899/000171489921000033/dnli-20201231.htm#1715503 Filing: 000171489921000033 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 197.61 million Exact value Exact value: -197614000 USD 2019-01-01 – 2019-12-31: -197614000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Denali Therapeutics Inc. · 2019-12-31 Denali Therapeutics Inc. (edgar:1714899) Net Income: -197614000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T23:15:23Z Snapshot: 913cbd83cd218e4e8bd06d80b237750247ba0058df259456e43d2aa2b5f864f5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1714899/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -197614000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1714899/000171489922000058/dnli-20211231.htm#2613983 Filing: 000171489922000058 The citation records this snapshot. The page link may show a newer release later.	−USD 151.58 million Exact value Exact value: -151576000 USD 2019-01-01 – 2019-12-31: -151576000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Denali Therapeutics Inc. · 2019-12-31 Denali Therapeutics Inc. (edgar:1714899) Operating Cash Flow: -151576000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T23:15:23Z Snapshot: 913cbd83cd218e4e8bd06d80b237750247ba0058df259456e43d2aa2b5f864f5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1714899/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -151576000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1714899/000171489922000058/dnli-20211231.htm#1670682 Filing: 000171489922000058 The citation records this snapshot. The page link may show a newer release later.	USD 17.92 million Exact value Exact value: 17919000 USD 2019-01-01 – 2019-12-31: 17919000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Denali Therapeutics Inc. · 2019-12-31 Denali Therapeutics Inc. (edgar:1714899) Capital Expenditure: 17919000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T23:15:23Z Snapshot: 913cbd83cd218e4e8bd06d80b237750247ba0058df259456e43d2aa2b5f864f5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1714899/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 17919000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1714899/000171489922000058/dnli-20211231.htm#1677664 Filing: 000171489922000058 The citation records this snapshot. The page link may show a newer release later.	−USD 169.5 million Calculation and evidence -151576000 − 17919000 USD Exact free cash flow: -169495000 USD 2019-01-01 – 2019-12-31: -151576000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 17919000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Denali Therapeutics Inc. · 2019-12-31 Denali Therapeutics Inc. (edgar:1714899) Free cash flow: -169495000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T23:15:23Z Snapshot: 913cbd83cd218e4e8bd06d80b237750247ba0058df259456e43d2aa2b5f864f5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1714899?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -151576000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1714899/000171489922000058/dnli-20211231.htm#1670682 Filing: 000171489922000058 Input fundies:CapitalExpenditure: 17919000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1714899/000171489922000058/dnli-20211231.htm#1677664 Filing: 000171489922000058 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	USD 71.14 million Exact value Exact value: 71136000 USD 2020-01-01 – 2020-12-31: 71136000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Denali Therapeutics Inc. · 2020-12-31 Denali Therapeutics Inc. (edgar:1714899) Net Income: 71136000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T23:15:23Z Snapshot: 913cbd83cd218e4e8bd06d80b237750247ba0058df259456e43d2aa2b5f864f5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1714899/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: 71136000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1714899/000171489923000049/dnli-20221231.htm#2513039 Filing: 000171489923000049 The citation records this snapshot. The page link may show a newer release later.	USD 416.15 million Exact value Exact value: 416152000 USD 2020-01-01 – 2020-12-31: 416152000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Denali Therapeutics Inc. · 2020-12-31 Denali Therapeutics Inc. (edgar:1714899) Operating Cash Flow: 416152000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T23:15:23Z Snapshot: 913cbd83cd218e4e8bd06d80b237750247ba0058df259456e43d2aa2b5f864f5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1714899/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 416152000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1714899/000171489923000049/dnli-20221231.htm#1617403 Filing: 000171489923000049 The citation records this snapshot. The page link may show a newer release later.	USD 3.1 million Exact value Exact value: 3095000 USD 2020-01-01 – 2020-12-31: 3095000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Denali Therapeutics Inc. · 2020-12-31 Denali Therapeutics Inc. (edgar:1714899) Capital Expenditure: 3095000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T23:15:23Z Snapshot: 913cbd83cd218e4e8bd06d80b237750247ba0058df259456e43d2aa2b5f864f5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1714899/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3095000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1714899/000171489923000049/dnli-20221231.htm#1624396 Filing: 000171489923000049 The citation records this snapshot. The page link may show a newer release later.	USD 413.06 million Calculation and evidence 416152000 − 3095000 USD Exact free cash flow: 413057000 USD 2020-01-01 – 2020-12-31: 416152000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 3095000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Denali Therapeutics Inc. · 2020-12-31 Denali Therapeutics Inc. (edgar:1714899) Free cash flow: 413057000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T23:15:23Z Snapshot: 913cbd83cd218e4e8bd06d80b237750247ba0058df259456e43d2aa2b5f864f5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1714899?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 416152000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1714899/000171489923000049/dnli-20221231.htm#1617403 Filing: 000171489923000049 Input fundies:CapitalExpenditure: 3095000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1714899/000171489923000049/dnli-20221231.htm#1624396 Filing: 000171489923000049 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 290.58 million Exact value Exact value: -290581000 USD 2021-01-01 – 2021-12-31: -290581000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Denali Therapeutics Inc. · 2021-12-31 Denali Therapeutics Inc. (edgar:1714899) Net Income: -290581000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T23:15:23Z Snapshot: 913cbd83cd218e4e8bd06d80b237750247ba0058df259456e43d2aa2b5f864f5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1714899/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -290581000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1714899/000171489924000086/dnli-20231231.htm#2072028 Filing: 000171489924000086 The citation records this snapshot. The page link may show a newer release later.	−USD 211.39 million Exact value Exact value: -211389000 USD 2021-01-01 – 2021-12-31: -211389000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Denali Therapeutics Inc. · 2021-12-31 Denali Therapeutics Inc. (edgar:1714899) Operating Cash Flow: -211389000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T23:15:23Z Snapshot: 913cbd83cd218e4e8bd06d80b237750247ba0058df259456e43d2aa2b5f864f5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1714899/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -211389000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1714899/000171489924000086/dnli-20231231.htm#1488447 Filing: 000171489924000086 The citation records this snapshot. The page link may show a newer release later.	USD 8.5 million Exact value Exact value: 8500000 USD 2021-01-01 – 2021-12-31: 8500000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Denali Therapeutics Inc. · 2021-12-31 Denali Therapeutics Inc. (edgar:1714899) Capital Expenditure: 8500000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T23:15:23Z Snapshot: 913cbd83cd218e4e8bd06d80b237750247ba0058df259456e43d2aa2b5f864f5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1714899/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 8500000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1714899/000171489924000086/dnli-20231231.htm#1493057 Filing: 000171489924000086 The citation records this snapshot. The page link may show a newer release later.	−USD 219.89 million Calculation and evidence -211389000 − 8500000 USD Exact free cash flow: -219889000 USD 2021-01-01 – 2021-12-31: -211389000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 8500000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Denali Therapeutics Inc. · 2021-12-31 Denali Therapeutics Inc. (edgar:1714899) Free cash flow: -219889000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T23:15:23Z Snapshot: 913cbd83cd218e4e8bd06d80b237750247ba0058df259456e43d2aa2b5f864f5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1714899?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -211389000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1714899/000171489924000086/dnli-20231231.htm#1488447 Filing: 000171489924000086 Input fundies:CapitalExpenditure: 8500000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1714899/000171489924000086/dnli-20231231.htm#1493057 Filing: 000171489924000086 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 325.99 million Exact value Exact value: -325991000 USD 2022-01-01 – 2022-12-31: -325991000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Denali Therapeutics Inc. · 2022-12-31 Denali Therapeutics Inc. (edgar:1714899) Net Income: -325991000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T23:15:23Z Snapshot: 913cbd83cd218e4e8bd06d80b237750247ba0058df259456e43d2aa2b5f864f5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1714899/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -325991000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1714899/000171489925000066/dnli-20241231.htm#2055093 Filing: 000171489925000066 The citation records this snapshot. The page link may show a newer release later.	−USD 244.72 million Exact value Exact value: -244716000 USD 2022-01-01 – 2022-12-31: -244716000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Denali Therapeutics Inc. · 2022-12-31 Denali Therapeutics Inc. (edgar:1714899) Operating Cash Flow: -244716000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T23:15:23Z Snapshot: 913cbd83cd218e4e8bd06d80b237750247ba0058df259456e43d2aa2b5f864f5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1714899/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -244716000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1714899/000171489925000066/dnli-20241231.htm#1444126 Filing: 000171489925000066 The citation records this snapshot. The page link may show a newer release later.	USD 17.83 million Exact value Exact value: 17833000 USD 2022-01-01 – 2022-12-31: 17833000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Denali Therapeutics Inc. · 2022-12-31 Denali Therapeutics Inc. (edgar:1714899) Capital Expenditure: 17833000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T23:15:23Z Snapshot: 913cbd83cd218e4e8bd06d80b237750247ba0058df259456e43d2aa2b5f864f5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1714899/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 17833000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1714899/000171489925000066/dnli-20241231.htm#1450769 Filing: 000171489925000066 The citation records this snapshot. The page link may show a newer release later.	−USD 262.55 million Calculation and evidence -244716000 − 17833000 USD Exact free cash flow: -262549000 USD 2022-01-01 – 2022-12-31: -244716000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 17833000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Denali Therapeutics Inc. · 2022-12-31 Denali Therapeutics Inc. (edgar:1714899) Free cash flow: -262549000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T23:15:23Z Snapshot: 913cbd83cd218e4e8bd06d80b237750247ba0058df259456e43d2aa2b5f864f5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1714899?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -244716000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1714899/000171489925000066/dnli-20241231.htm#1444126 Filing: 000171489925000066 Input fundies:CapitalExpenditure: 17833000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1714899/000171489925000066/dnli-20241231.htm#1450769 Filing: 000171489925000066 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 145.22 million Exact value Exact value: -145224000 USD 2023-01-01 – 2023-12-31: -145224000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Denali Therapeutics Inc. · 2023-12-31 Denali Therapeutics Inc. (edgar:1714899) Net Income: -145224000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T23:15:23Z Snapshot: 913cbd83cd218e4e8bd06d80b237750247ba0058df259456e43d2aa2b5f864f5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1714899/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -145224000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1714899/000171489926000021/dnli-20251231.htm#2089964 Filing: 000171489926000021 The citation records this snapshot. The page link may show a newer release later.	−USD 357.99 million Exact value Exact value: -357991000 USD 2023-01-01 – 2023-12-31: -357991000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Denali Therapeutics Inc. · 2023-12-31 Denali Therapeutics Inc. (edgar:1714899) Operating Cash Flow: -357991000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T23:15:23Z Snapshot: 913cbd83cd218e4e8bd06d80b237750247ba0058df259456e43d2aa2b5f864f5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1714899/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -357991000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1714899/000171489926000021/dnli-20251231.htm#1441891 Filing: 000171489926000021 The citation records this snapshot. The page link may show a newer release later.	USD 12.94 million Exact value Exact value: 12939000 USD 2023-01-01 – 2023-12-31: 12939000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Denali Therapeutics Inc. · 2023-12-31 Denali Therapeutics Inc. (edgar:1714899) Capital Expenditure: 12939000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T23:15:23Z Snapshot: 913cbd83cd218e4e8bd06d80b237750247ba0058df259456e43d2aa2b5f864f5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1714899/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 12939000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1714899/000171489926000021/dnli-20251231.htm#1448531 Filing: 000171489926000021 The citation records this snapshot. The page link may show a newer release later.	−USD 370.93 million Calculation and evidence -357991000 − 12939000 USD Exact free cash flow: -370930000 USD 2023-01-01 – 2023-12-31: -357991000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 12939000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Denali Therapeutics Inc. · 2023-12-31 Denali Therapeutics Inc. (edgar:1714899) Free cash flow: -370930000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T23:15:23Z Snapshot: 913cbd83cd218e4e8bd06d80b237750247ba0058df259456e43d2aa2b5f864f5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1714899?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -357991000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1714899/000171489926000021/dnli-20251231.htm#1441891 Filing: 000171489926000021 Input fundies:CapitalExpenditure: 12939000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1714899/000171489926000021/dnli-20251231.htm#1448531 Filing: 000171489926000021 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 422.77 million Exact value Exact value: -422773000 USD 2024-01-01 – 2024-12-31: -422773000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Denali Therapeutics Inc. · 2024-12-31 Denali Therapeutics Inc. (edgar:1714899) Net Income: -422773000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T23:15:23Z Snapshot: 913cbd83cd218e4e8bd06d80b237750247ba0058df259456e43d2aa2b5f864f5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1714899/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -422773000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1714899/000171489926000021/dnli-20251231.htm#2089201 Filing: 000171489926000021 The citation records this snapshot. The page link may show a newer release later.	−USD 347.69 million Exact value Exact value: -347694000 USD 2024-01-01 – 2024-12-31: -347694000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Denali Therapeutics Inc. · 2024-12-31 Denali Therapeutics Inc. (edgar:1714899) Operating Cash Flow: -347694000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T23:15:23Z Snapshot: 913cbd83cd218e4e8bd06d80b237750247ba0058df259456e43d2aa2b5f864f5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1714899/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -347694000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1714899/000171489926000021/dnli-20251231.htm#1441244 Filing: 000171489926000021 The citation records this snapshot. The page link may show a newer release later.	USD 15.91 million Exact value Exact value: 15912000 USD 2024-01-01 – 2024-12-31: 15912000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Denali Therapeutics Inc. · 2024-12-31 Denali Therapeutics Inc. (edgar:1714899) Capital Expenditure: 15912000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T23:15:23Z Snapshot: 913cbd83cd218e4e8bd06d80b237750247ba0058df259456e43d2aa2b5f864f5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1714899/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 15912000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1714899/000171489926000021/dnli-20251231.htm#1447946 Filing: 000171489926000021 The citation records this snapshot. The page link may show a newer release later.	−USD 363.61 million Calculation and evidence -347694000 − 15912000 USD Exact free cash flow: -363606000 USD 2024-01-01 – 2024-12-31: -347694000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 15912000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Denali Therapeutics Inc. · 2024-12-31 Denali Therapeutics Inc. (edgar:1714899) Free cash flow: -363606000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T23:15:23Z Snapshot: 913cbd83cd218e4e8bd06d80b237750247ba0058df259456e43d2aa2b5f864f5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1714899?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -347694000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1714899/000171489926000021/dnli-20251231.htm#1441244 Filing: 000171489926000021 Input fundies:CapitalExpenditure: 15912000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1714899/000171489926000021/dnli-20251231.htm#1447946 Filing: 000171489926000021 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 512.54 million Exact value Exact value: -512540000 USD 2025-01-01 – 2025-12-31: -512540000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Denali Therapeutics Inc. · 2025-12-31 Denali Therapeutics Inc. (edgar:1714899) Net Income: -512540000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T23:15:23Z Snapshot: 913cbd83cd218e4e8bd06d80b237750247ba0058df259456e43d2aa2b5f864f5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1714899/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -512540000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1714899/000171489926000021/dnli-20251231.htm#2088438 Filing: 000171489926000021 The citation records this snapshot. The page link may show a newer release later.	−USD 412.6 million Exact value Exact value: -412600000 USD 2025-01-01 – 2025-12-31: -412600000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Denali Therapeutics Inc. · 2025-12-31 Denali Therapeutics Inc. (edgar:1714899) Operating Cash Flow: -412600000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T23:15:23Z Snapshot: 913cbd83cd218e4e8bd06d80b237750247ba0058df259456e43d2aa2b5f864f5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1714899/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -412600000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1714899/000171489926000021/dnli-20251231.htm#1440594 Filing: 000171489926000021 The citation records this snapshot. The page link may show a newer release later.	USD 9.5 million Exact value Exact value: 9502000 USD 2025-01-01 – 2025-12-31: 9502000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Denali Therapeutics Inc. · 2025-12-31 Denali Therapeutics Inc. (edgar:1714899) Capital Expenditure: 9502000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T23:15:23Z Snapshot: 913cbd83cd218e4e8bd06d80b237750247ba0058df259456e43d2aa2b5f864f5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1714899/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 9502000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1714899/000171489926000021/dnli-20251231.htm#1447362 Filing: 000171489926000021 The citation records this snapshot. The page link may show a newer release later.	−USD 422.1 million Calculation and evidence -412600000 − 9502000 USD Exact free cash flow: -422102000 USD 2025-01-01 – 2025-12-31: -412600000 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 9502000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Denali Therapeutics Inc. · 2025-12-31 Denali Therapeutics Inc. (edgar:1714899) Free cash flow: -422102000 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T23:15:23Z Snapshot: 913cbd83cd218e4e8bd06d80b237750247ba0058df259456e43d2aa2b5f864f5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1714899?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -412600000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1714899/000171489926000021/dnli-20251231.htm#1440594 Filing: 000171489926000021 Input fundies:CapitalExpenditure: 9502000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1714899/000171489926000021/dnli-20251231.htm#1447362 Filing: 000171489926000021 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

123 filings · 2,260 latest values · 2,260 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001714899, 1714899, DNLI, edgar:1714899

Also known as Denali Therapeutics Inc.

Denali Therapeutics Inc.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Net income

Operating cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation